Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Novavax, Inc. is a biotechnology company specializing in vaccine development using recombinant nanoparticle technology and proprietary Matrix-M adjuvant. Its core focus is on infectious diseases, including COVID-19, influenza, and malaria, with a pipeline of vaccine candidates and collaborations worldwide. The company leverages scientific innovation, strategic partnerships, and a flexible manufacturing model to deliver immunogenic, scalable vaccines for global health markets.
This description was generated via AI from an annual report. Updated about 1 year ago.